Otherindependent cross-checkabstract only checked I-CHM-12 standard review
Cancer death rates in the USA keep falling
Cancer statistics, 2024.
Overview
Siegel RL et al.. CA Cancer J Clin 2024 · PMID 38230766 · DOI 10.3322/caac.21820
More than 4 million cancer deaths averted since 1991 thanks to less smoking, earlier detection and better treatment.
Does the study support the specific claim? No · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Report cancer statistics.
- How was the study done?
Registry data.
- How many people, animals or samples were studied?
US population.
- What was actually found?
Declining mortality.
- How large was the observed effect?
>4 million deaths averted.
- What do the results mean in everyday life?
Prevention and treatment both work.
- What are the study's limitations?
Descriptive.
- What does it say about Elawady's specific claim?
Benefit context.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Share due to treatment alone.
Scientific in-depth review
1. Full reference
- Authors
- Siegel RL et al.
- Journal
- CA Cancer J Clin
- Year
- 2024
- Identifier
- PMID 38230766 DOI 10.3322/caac.21820
- Verification
- verified – PubMed esummary + efetch 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract
2. Research question
Cancer incidence and mortality in the USA.
3. Study design and population
- Study design
- Other – Descriptive national statistics report
- Population
US population
- Country
USA
- Period
Incidence through 2020; mortality through 2021
- Sample size
Population data
4. Methods and endpoints
- Endpoints
Incidence, mortality
- Statistical methods
Descriptive trends
5. Actual results
- Results
Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection and improved treatment (adjuvant and metastatic). Incidence rising for 6 of top 10 cancers.
- Absolute risks
Over 4 million deaths averted since 1991
- Authors' conclusion
Progress requires investment in prevention and equitable treatment access.
6. Strengths
- Complete national data
7. Weaknesses
- Attribution to causes is not quantified per cause in abstract
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- not assessable
- Rationale
Descriptive.
9. Assessment of the statistical interpretation
Population trends; causal shares not separable in abstract.
10. Relevance to the specific claim
Population-level evidence that treatment (with smoking reduction and screening) reduced cancer mortality.
11. Independent contrary findings
12. Transferability to Germany and Europe
Moderate.
13. Overall methodological judgement
Context evidence.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | not assessable |
| Precision of results | high |
| Directness | indirect |
| Reproducibility | unknown |
| Consistency with the overall evidence | unknown |
| Regional transferability | moderate |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
15. Linked fact checks
- The archive's 19 chemo/radiation studies are presented on the homepage as 'scientific studies confirming what Dr. Diaa proposed'; the harm-only study selection implies that the harms of chemotherapy and radiotherapy outweigh their benefits. – Studies contradicting or limiting the claim
- Oncology only buys time: 'survival rates' are meaningless, patients die during treatment, and early diagnosis only makes you 'die early'. – Studies contradicting or limiting the claim
- Smoking (and similar exposures) should not be blamed for cancer; only massive exposures such as Hiroshima cause cancer, and there is 'no such thing as early death' from smoking. – Studies contradicting or limiting the claim